2022-07-18T00:00:00.000+10:00
Ongoing

ASCENT 04

ASCENT 04
Breast cancer

A study of sacituzumab govitecan-hziy and pembrolizumab versus treatment of physician's choice and pembrolizumab in patients with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer (ASCENT 04 – GS-US-592-6173)

A study of sacituzumab govitecan-hziy and pembrolizumab versus treatment of physician's choice and pembrolizumab in patients with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer (ASCENT 04 – GS-US-592-6173)

Trial overview

Topic

Breast cancer

Trial registration

Number: NCT05382286

Study details

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).

Further information

Please click here for more information

Location

GenesisCare North Shore – PI: Dr Sally Baron-Hay

GenesisCare North Shore – PI: Dr Sally Baron-Hay :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.